Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Sanofi ADR (SNY)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Sanofi ADR's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create a new watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
48.38 +0.19    +0.39%
17/09 - Closed. Currency in USD ( Disclaimer )
After Hours
48.80
+0.42
+0.87%
18:36:25 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US80105N1054 
CUSIP:  80105N105
  • Volume: 7,601,030
  • Bid/Ask: 47.60 / 49.40
  • Day's Range: 47.69 - 48.43
Sanofi ADR 48.38 +0.19 +0.39%

SNY Analysis

 
This page features the latest analysis and reports for the Sanofi ADR stock.
Zacks Investment Research
6 Best ETF Areas of August By Zacks Investment Research - Aug 31, 2021

Wall Street delivered a decent performance last month with the S&P 500 and the Dow Jones adding 1.5% each and the Nasdaq Composite gaining about 3.1%. The Russell 2000 Index has advanced about...

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

SNY Comments

Write your thoughts about Sanofi ADR
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
gino freeboter
gino freeboter May 03, 2021 9:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what is going on?why drop 4% inpremarket?
Reply
1 0
Report
Aspar Badur
Aspar Badur May 03, 2021 9:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
don’t know 🤷‍♂️
Reply
0 0
Report
Päivi Saarela
Päivi Saarela Apr 26, 2021 8:23AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
NEWS: Sanofi agrees to make Moderna COVID-19 vaccine in the U.S. starting in September
Reply
0 0
Report
Brad Eff
Brad Eff Mar 31, 2021 10:10AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Announcement RIGHT NOW about a +$900 Million investment in Canada
Reply
1 0
Report
Akposiegbe Kelvin
Akposiegbe Kelvin Feb 14, 2021 10:28AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
sanofi said it's vaccine will be available next year..
Reply
1 0
Report
Renata Hoffmann
Renata Hoffmann Feb 14, 2021 10:28AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
but they have more products in pipeline...not just the vaccine
Reply
0 0
Report
Renata Hoffmann
Renata Hoffmann Feb 11, 2021 8:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Whi is it falling? FDA approval end its going down?
Reply
1 0
Report
Omprakash Maurya
Omprakash Maurya Feb 05, 2021 10:18AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Next target 52 buy at 48
Reply
0 0
Report
Tejasvi Gogna
Tejasvi Gogna Aug 13, 2020 7:05PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ARPO a small stock has given me 22% rise , that too on a day when all others have disappointed . Nova , Mrna , Bntx , Astra , Sanofi ... Seriously I salute to the guys running ARPO. .. its been so stable when all others are horribly unpredictable. ARPO has hd its base value and maintained its 1.5 level and Now its on 1.83 and after market is up again. highly recommended if someone wants to invest 1000 dollars and forget it for a while , I am sure its worth putting your 💰......
Reply
1 0
Report
RoB Wanger
RoB Wanger Jul 31, 2020 11:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://ca.finance.yahoo.com/news/u-pay-2-1-billion-122206294.html
Reply
0 0
Report
BullBear TopTrader
BullBear TopTrader May 15, 2020 7:21PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
TONIX PHARMACEUTICALS - WILL PRESENT CERTAIN INFORMATION REGARDING ITS VACCINE CANDIDATES TARGETING COVID-19 AT A  panel on may 19
Reply
2 3
Report
Zack Lewis
Zack Lewis Apr 23, 2020 12:42PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
come on, you had good news today, why not going up?
Reply
1 0
Report
Money Guru
Money Guru Apr 17, 2020 12:59PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Companies upside looks unbelievable its the next awaiting Gilead. Partnering up with moderna, supporting the coronavirus outbreak with strong balance sheet. Its a must buy.
Reply
2 0
Report
Monkeith Muhammad
Monkeith Muhammad Apr 07, 2020 10:43PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
President Donald Trump reportedly owns a stake in a company that produces hydroxychloroquine, the anti-malaria drug he has repeatedly touted as a coronavirus treatment even though his experts say there’s no strong evidence it works. 
Reply
1 2
Report
John Simmons Simmons
John Simmons Simmons Mar 23, 2020 12:26AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Dear Mr. Abbas Otobus., I would like to suggest you without any responsibility my personal investment to invest in Curetis NV and OpGen ., what do you think Sir ?
Reply
0 0
Report
abbas otobus
abbas otobus Mar 19, 2020 4:23PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Probably will gain too much in next 6 months because of using hydroxychloroquine for covid-19 prophylaxis and treatment
Reply
3 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email